Evaluation of MVA-5T4 As a Novel Immunotherapeutic Vaccine in Colorectal, Renal and Prostate Cancer

10.1517/14712598.7.9.1463

10.1016/j.addr.2006.05.005

10.2741/1838

10.1038/bjc.1994.173

10.1038/sj.bjc.6602776

10.1002/dvdy.20482

10.1038/bjc.1988.53

10.1038/bjc.1990.20

10.1371/journal.pone.0009982

10.1073/pnas.89.22.10847

10.1007/s00262-005-0096-4

Mulryan K , RyanMG, MyersKAet al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 1, 1129–1137 (2002).

10.1158/1078-0432.CCR-05-2732

10.1007/s00262-007-0428-7

10.1158/1078-0432.CCR-07-0704

10.1007/s00262-009-0674-y

10.1097/CJI.0b013e31819d297e

10.1097/CJI.0b013e3181ace876

10.1186/1479-5876-7-2

10.1158/1078-0432.CCR-08-0668

10.1097/CJI.0b013e31817deafd

Amato RJ , HawkinsRE, KaufmanHLet al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled Phase III study. Cancer Res. 16(22), 5539–5547 (2010).

10.1056/NEJMoa065044

10.1016/S1471-4892(03)00071-7

10.1056/NEJMoa066838

10.1007/s00262-011-0993-7

American Cancer Society. Cancer Facts and Figures 2011. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf